Resistance surveillance in Italy: Four-year results from the MYSTIC program

Journal of Chemotherapy

Volumn 14, Issue 4, 2002, Pages 323-331

  Fontana, R ^a   Lo Cascio, G ^a   Giacobone, E ^a   Romero, E ^a   Cipriani, P ^a   Sessa, R ^a   Franchino, Luigi ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Antimicrobial activity; Meropenem; MYSTIC program; Nosocomial infections; Pseudomonas aeruginosa

Indexed keywords

ANTIMIGRAINE AGENT; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATION; CONTROLLED STUDY; DRUG POTENCY; DRUG SURVEILLANCE PROGRAM; ENTEROBACTERIACEAE; ESCHERICHIA COLI; HOSPITAL INFECTION; ITALY; NONHUMAN; PSEUDOMONAS AERUGINOSA; TREATMENT INDICATION;

EID: 0036693984     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2002.14.4.323     Document Type: Article

References (29)

1. The changing pattern of infection in neutropenic patients
2. Rapid emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients due to in-vivo selection of stable partially derepressed beta-lactamase producing strains
3. Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients
4. The Alexander Project 1996-1997: Latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections
5. Bacterial pathogens isolated from patients with bloodstream infection: Frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997)
6. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1990-May 1999
7. Nosocomial blood stream infections in United States hospitals: A three-year analysis
8. Surveillance of antimicrobial resistance: The WHONET program
9. Standardization and quality assurance for antimicrobial surveillance of Streptococcus pneumoniae and Staphylococcus aureus within the European Antimicrobial Resistance Surveillance System (EARSS)
10. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: Project ICARE phase 2
11. The mystic (Meropenem Yearly Susceptibility Test Information Collection) programme
12. In-vitro studies of meropenem
13. A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated worldwide
14. A compilation of studies assessing the in vitro activity of meropenem and comparators in 84 laboratories throughout Europe
15. Antimicrobial resistance in Gram-negative isolates from European Intensive Care Units: Data from the meropenem yearly susceptibility test information collection (MYSTIC) programme
16. Enterobacter spp.: A pathogen poised to flourish at the turn of the century
17. Antibiotic resistance in Pseudomonas aeruginosa: An Italian survey
18. Imipenem resistance in Pseudomonas aeruginosa resulting from diminished expression of an outer membrane protein
19. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: Active efflux as a contributing factor to beta-lactam resistance
20. Appearance of IMP-1 metallo-beta-lactamase in Europe
21. Structure-activity relationships of carbapenems that determine their dependence on porin protein D2 for activity against Pseudomonas aeruginosa
22. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: Resistance implications in the treatment of serious infections
23. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Europe: Comparison of antibiotic susceptibilities between countries and centre types
24. Use of carbapenems and other antibiotics for pulmonary infections in patients with cystic fibrosis
25. Meropenem in cystic fibrosis patients infected with resistant Pseudomonas aeruginosa or Burkholderia cepacia and with hypersensitivity to beta-lactam antibiotics
26. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer
27. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalised patients